FDA Panel Vote Lifts Restrictions on Six Unapproved Peptides
An FDA advisory panel narrowly voted to recommend lifting restrictions on six unapproved peptides, leading HHS to announce it will not enforce against compounders making them, a move that expands access but raises significant safety concerns.
The FDA has lifted restrictions on six unapproved peptides, enabling compounding pharmacies to produce them. This follows a narrow vote by an FDA advisory panel in July 2026 to recommend adding KPV, TB-500, BPC-157, MOTS-c, Semax, and Epitalon to the list of bulk drug substances permitted for compounding. The Department of Health and Human Services announced it will not take enforcement action against state-licensed pharmacies, federal facilities, or licensed doctors who compound these substances, exercising enforcement discretion as outlined in a Federal Register notice published on October 29, 2026. The policy does not include emideltide, which the panel voted against.
HHS Enforcement Discretion Permits Compounding Without FDA Approval
Under the new interim policy, small compounding pharmacies can produce the six peptides without prior FDA approval. They must, however, certify the identity and purity of the compounds and report any side effects, obligations that were not previously mandated. The FDA's standard process to add an ingredient to the bulk list involves proposing a rule, taking public comment, and issuing a final rule, which can take several months. This enforcement discretion effectively pulls forward patient access by that timeframe. HHS and the FDA jointly submitted the interim policy to the Office of Management and Budget on October 14, 2026, and the department is now accepting public comments on it for two weeks.
Black and Gray Markets Persist Despite New Policy
Demand for these peptides, which the FDA has not approved for any human use, has already spurred significant black and gray markets. The policy is intended to provide a more controlled alternative through licensed U.S. compounders, moving consumers away from retailers who sell peptides labeled 'for research use only' as a legal workaround. Health Secretary Robert F. Kennedy Jr., a vocal supporter who has used the peptides himself, argues that allowing legal compounding will steer people toward safer products. Critics counter that the policy fails to address core safety issues. Fred Mills said: "A legal pathway does not resolve problems with untested products, safety risks, questionable ingredients, or misleading claims."
Safety Concerns and Industry Opposition Remain Unresolved
The FDA itself has expressed deep reservations. The agency identified the peptides as posing 'significant safety risks' in 2023 and its own scientists have concluded there is insufficient data to prove they are safe and effective. The FDA refused to support a regulation calling the peptides safe. A memo accompanying the policy stated that FDA staff safety concerns were 'more mechanistic rather than observed' and lacked an empirical basis. The advisory panel that made the recommendation included six new appointees with ties to the peptide industry and another who is the son of a U.S. representative who has pushed for greater peptide access. Robert Steinbrook said: "Kennedy has undermined the FDA and threatened public health."
Telehealth Market Poised for Growth Amid Policy Shift
The regulatory shift is seen as a potential catalyst for the telehealth peptide market. Leerink Partners analyst Michael Cherny described the policy as a 'yellow light' for telemedicine companies like Hims & Hers, though not a full 'green light' for market entry. Cherny had previously estimated the peptide telehealth market could be worth between $1.1 billion and $2.2 billion annually. The policy flips the regulatory default, requiring products to be proven unsafe before action is taken, a framework that converts pharmaceutically active compounds into something closer to supplements. Rare-disease advocates are expected to demand similar access and freedoms, drawing a direct line to the right-to-try debate.
States may choose not to implement the policy due to the federal-state split in compounding oversight. The Partnership for Safe Medicines has filed a citizen petition against the order, but legal experts are unsure a court challenge is available because the policy is interim. Litigation may require a final regulation. The policy is expected to remain in place as long as Robert F. Kennedy Jr. leads HHS or beyond.
